Zimberelimab monotherapy was tested in a single arm, phase II study, showing promising prolonged tumor responses (6-month DoR rate: 84%, 95% CI, 58 to 95%), clinically meaningful antitumor activity, significantly higher compared to historical controls (ORR: 27.8%, 95% CI: 18.85 to 38.22) and acceptable toxicity in PD-L1 positive, CC patients in the post-platinum setting, after a median follow-up of 11.5 months (Table 1) [18]. This evidence concerns the gene CD274 and neoplasm.